SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the leader in continuous glucose monitoring (CGM) for people with diabetes, announced today that it incorporated Ambulatory Glucose Profile (AGP) into its Dexcom CLARITY software. A web-based software, Dexcom CLARITY provides access to clinically relevant metrics and reports for data analyses and diabetes management planning.
The Ambulatory Glucose Profile report, known as captūrAGP®, was developed by the International Diabetes Center (IDC), with input from endocrinologists and clinicians who are experts in data management and interpretation.1,2 AGP includes a summary of patient glucose data in three parts: (1) statistical summary, (2) visual display, and (3) daily views. These components create a common platform for patients and clinicians to view glucose patterns and trends.
"Dexcom is pleased to partner with the IDC in implementing a standard report across all platforms – allowing physicians and health care professionals to compare information in a consistent format," said Kevin Sayer, President and Chief Executive Officer, Dexcom. "As the industry leader in continuous glucose monitoring, it is important that we align with industry recommendations and clinical societies to provide the tools and information needed to help clinicians improve clinic work flow while managing their patients’ diabetes with glucose data and reporting.”
Dexcom will be featuring the new updates to Dexcom CLARITY, including AGP, at the American Diabetes Association’s 77th Scientific Sessions in San Diego, CA, from June 10-12, 2017. Dexcom will have Dexcom CLARITY experts available to demo the software in booth 2135.
“I hope that utilizing the AGP to standardize CGM metrics and the glucose profile display will help clinicians and patients together to formulate a personalized action plan to optimize glucose control,” says Richard Bergenstal, MD, Endocrinologist and Executive Director of the International Diabetes Center, St Louis Park, MN.
“AGP reports have been used for several years by physicians,” explained George Grunberger, MD, FACP, FACE, Chairman of the Grunberger Diabetes Institute in Bloomfield Hills, MI and immediate past-president of AACE (2015-2016), “and presents the most relevant statistical and graphical information that would allow clinicians to quickly assess the glucose control of a patient and make meaningful clinical decisions. By having a wider adoption of this report by medical device companies, it allows the information to be agnostic to the manufacturer. AGP can become the EKG report of diabetology – where there is one standard glucose report that all clinicians can interpret.”
About DexCom, Inc.
DexCom, Inc., headquartered in San Diego, CA, is
dedicated to helping people better manage their diabetes by developing
and marketing continuous glucose monitoring (CGM) products and tools for
adult and pediatric patients. With exceptional performance, patient
comfort and lifestyle flexibility at the heart of its technology, users
have consistently ranked Dexcom highest in customer satisfaction and
loyalty. For more information on the Dexcom CGM, visit www.dexcom.com.
To view multimedia assets, please visit: http://www.dexcom.com/media.
1.
Bergenstal RM, Ahmann A, Bailey T, et al. Recommendations for
standardizing glucose reporting and analysis to optimize clinical
decision making in diabetes: the Ambulatory Glucose Profile (AGP). Diabetes
Technol Ther. 2013;15:198-211.
2. Mullen DM. (2017,
February 1). AGP [Online]. Available at: www.AGPreport.org.
